|
IL1RAP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
5.82449999999568E-05 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
3.55881990543594E-12 |
| Stage1-vs-Stage2 |
4.689600E-02 |
| Stage1-vs-Stage3 |
4.307000E-01 |
| Stage1-vs-Stage4 |
4.400400E-01 |
| Stage2-vs-Stage3 |
1.712840E-01 |
| Stage2-vs-Stage4 |
2.858300E-02 |
| Stage3-vs-Stage4 |
1.750760E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.56962999999788E-05 |
| Normal-vs-Asian |
8.98260354986746E-11 |
| Caucasian-vs-AfricanAmerican |
4.713200E-01 |
| Caucasian-vs-Asian |
9.994000E-01 |
| AfricanAmerican-vs-Asian |
4.965000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
4.305400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
4.67337279985713E-12 |
| Normal-vs-Age(81-100Yrs) |
6.440300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.754800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.229700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.922220E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.709990E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.609200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.853000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.506800E-01 |
| Classical-VS-Follicular |
<1E-12 |
| Classical-VS-Other |
2.329200E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
5.89961413055562E-12 |
| Tall-VS-Other |
1.358980E-01 |
| Tall-VS-Normal |
2.84816614737338E-12 |
| Follicular-VS-Other |
2.176200E-01 |
| Follicular-VS-Normal |
5.71969999999533E-05 |
| Other-VS-Normal |
6.898400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62458935193399E-12 |
| Normal-vs-N1 |
6.57252030578093E-14 |
| N0-vs-N1 |
2.764400E-02 |
|
|
